2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 22

Monoclonal Anti-Citrullinated Protein Antibodies Generated from RA-Derived B Cells Recognize Amino Acid Motifs Rather Than Specific Proteins
Abstract Number: 365

Monoclonal Gammopathy in Rheumatic Diseases
Abstract Number: 125

Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation
Abstract Number: 2043

Monocytes and Macrophages of Patients with Rheumatoid Arthritis Respond to Pathologically Increased Ionized Calcium with Proinflammatory Cytokine Production
Abstract Number: 1009

Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis
Abstract Number: 2235

Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
Abstract Number: 2097

Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Abstract Number: 1171

Mortality Among Those with OA: Time-Varying Effects of Socioeconomic Measures
Abstract Number: 212

Mortality and Causes of Death in Patients with Inflammatory Arthritis in Hong Kong over 20 Years
Abstract Number: 2136

Mortality Rates and Causes in Psoriatic Arthritis Patients
Abstract Number: 1331

Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Abstract Number: 1445

MRI Bone Erosions in RA Patients Relatives with Clinically Suspicious Arthralgia
Abstract Number: 654

MRI Lesion Definitions in Axial Spondyloarthritis: A Consensus Reappraisal from the Assessments in Spondyloarthritis International Society
Abstract Number: 1819

MUC5B promoter Variant rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease
Abstract Number: 1789

Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].